ReviewTranslational lung cancer research2025
Immune-oncology-microbiome axis in lung cancer: from carcinogenesis to therapy-a narrative review.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut-lung axis in radiation-induced lung injury: mechanisms and interventions.Frontiers in immunology · 2026Review
- Mucosal immunity in cancer metastasis: roles, mechanisms, and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Recent studies have increasingly highlighted the critical role of the microbiome in lung cancer initiation, progression, metastasis, and therapeutic resistance. Microbial dysbiosis has been identified as a significant risk factor for lung cancer progression. Beyond the gut, emerging evidence shows that microorganisms also colonize the lungs and even inside tumors, suggesting a broader role of the microbiome in the disease. This review explores the immune-oncology-microbiome (IOM) axis by examining microbial communities across different anatomical sites, their interactions with the tumor immune microenvironment, and their impact on immunotherapy efficacy in lung cancer. Methods: We conducted a systematic literature search using PubMed and Web of Science databases for English-language articles published between 2014 and 2025, using key terms related to lung cancer and microbiome. Key Content and Findings: The microbiome associated with lung cancer encompasses gut microbiota, lower respiratory tract microbiota, and intratumor microbiota. Different microbial communities maintain microecological homeostasis and modulate antitumor immune responses by shaping the tumor immune microenvironment. Meanwhile, certain microbiota can enhance or hinder the effectiveness of immunotherapy. Conclusions: The IOM axis reveals dynamic interactions between immune cells, cancer cells, and microbes. Specific microbe-derived metabolites show promise as lung cancer biomarkers. Current microbiome-based therapy shows great potential in lung cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.